Trade-offs should be carefully considered, as data have indicated that many QoL factors eventually even out.
Women and men were found to react differently to treatment with chemotherapy, although gender-based survival differences were not observed.
By way of the TAPUR study, researchers are attempting to evaluate the activity of targeted therapies when they are used in an off-label setting.
Dr Vorobiof discusses the importance patient factors that can be missed via standard data collection methods for patients with cancer.
Image-guided microwave ablation of early-stage renal tumors shows promise but a new retrospective study from the Mayo Clinic found some cases of major bleeding.
Utilizing data from the PREVAIL dataset, researchers developed mathematical models that can provide prognostic information for men being treated with enzalutamide for chemotherapy-naïve metastatic castration-resistant prostate cancer.
Omega-3 fatty acids found in fish oil act through a host receptor, GPR120, to confer anti-prostate cancer effects. Additional studies are underway.
Radiotherapy may improve survival among men with low metastatic burden, but not in all patients with metastatic prostate cancer.
A high prevalence of patients with renal cell carcinoma reported distress, highlighting the need for better psychosocial screening of patients.
Researchers found a microRNA signature in urine that can predict the presence of bladder cancer, advancing the idea of a noninvasive diagnostic test.
Evaluation of patient-reported outcomes (PROs) is an important component of measuring quality in cancer care.
Dr Ross described how genomic reports may need to be updated to account for new insights into a variant's role in cancer.
PD-L1 tumor expression was found not to be a predictive biomarker for cabozantinib efficacy in mRCC.
The regimen did not improve survival and increased bone fractures.
A ctDNA testing method has the capability to predict cancer recurrence, which could help guide therapy selections and uncover new drug development opportunities.
Findings from the SPARTAN trial show that HRQoL is not diminished by adding apalutamide to androgen deprivation therapy in men with asymptomatic, nonmetastatic CRPC.
Researchers clarified the role of miR-125a-5p in bladder cancer, showing that it inhibits bladder cancer progression by targeting oncogene FUT4.
A retrospective study found EGFR and HER2 overexpression associated with clinical features, such as tumor stage and tumor recurrence, in bladder cancer tissue.
In a recently published study, external beam radiation therapy for localized prostate cancer was associated with a 35% increased risk of bladder cancer compared with radical prostatectomy.
Men treated with radical prostatectomy plus radiotherapy for locally or regionally advanced prostate cancer had improved survival but worse adverse events.
Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?October 04, 2018
In clinical practice, most physicians and nurse practitioners do not feel comfortable enough with their medical knowledge of cannabis to offer it to patients.
Long-term oncologic outcomes of patients with sporadic RCC who underwent robotic tumor enucleation suggest the procedure is safe.
Dr José Baselga failed to disclose his financial ties to pharmaceutical companies in top-tier journals, causing many to question whether conflicts of interest are being properly reported.
Patients at VA facilities with high-risk early-stage bladder cancer tend to have cystoscopic surveillance at frequencies similar to those with low-risk disease.
Treatment with NAC did not transform the prevailing subtype in bladder cancer — instead, shifts in cancer subtype were attributed to tumor plasticity.
Differences in TMB between African and European patients show that "racial mutational disparity is not a technical or computational artifact," according to authors.
Researchers found that doubling in KIM-1 plasma concentrations was associated with an increased risk of developing RCC and poorer survival.
Epigenetic changes in the tumor microenvironment may explain why prostate cancer patients develop resistance to androgen signaling deprivation therapy.
Researchers propose a treatment algorithm to clarify treatment options beyond the first line for metastatic urothelial carcinoma of the bladder.
Supply Shortages of Bacillus Calmette-Guérin Found to Spur Drug Rationing in Non-Muscle-Invasive Bladder CancerSeptember 21, 2018
BCG shortages did not appear to influence the incidence of radical cystectomy, but evidence of drug rationing was revealed.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- CAR-T Trial for Triple-Negative Breast Cancer Under Way
- Daratumumab Combination: New Standard of Care in Transplant-Ineligible Multiple Myeloma
- Adjuvant Trastuzumab Emtansine Confers Improved Outcome in KATHERINE Trial
- Phase 3 GEICAM/CIBOMA Results: Adjuvant Capecitabine in Triple-Negative Breast Cancer
- Extension of Adjuvant Anastrozole Regimen to 10 Years Yields Higher DFS, but Not OS
- Selinexor Trials Move Nuclear Suppressor Protein-Export Inhibition Closer to the Clinic for Multiple Myeloma
- Younger Breast Cancer Patients at Higher Risk for Osteoporosis
- Molecular Mechanisms Underlying Immunosurveillance in Multiple Myeloma Identified
- Gly101Val Mutation Directly Causes Resistance to Venetoclax
- Can Treatments for Childhood ALL Alter the Gut Microbiome?